CordLife (Hong Kong) Ltd and China Cord Blood Corporation Marketing Collaboration AgreementMarketing Collaboration Agreement • September 28th, 2011 • China Cord Blood Corp • Blank checks • Hong Kong
This Marketing Collaboration Agreement (“Agreement”) is dated the date specified on the execution page of this Agreement.
TOMarketing Collaboration Agreement • June 28th, 2004 • Osi Pharmaceuticals Inc • In vitro & in vivo diagnostic substances • New York
AMENDMENT #3 TO THE RESEARCH, DEVELOPMENT AND MARKETING COLLABORATION AGREEMENT BETWEEN ONYX PHARMACEUTICALS, INC. AND WARNER-LAMBERT COMPANYMarketing Collaboration Agreement • November 14th, 2001 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances)
THIS AMENDMENT #3 to the Research, Development and Marketing Collaboration Agreement dated as of July 31, 1997 (“Third Amendment”) is made and entered into on August 6, 2001 (the “Amendment Date”), by and between Onyx Pharmaceuticals, Inc., a Delaware corporation having its principal place of business at 3031 Research Drive, Richmond, California 94806 (“Onyx”), and the Warner-Lambert Company, a Delaware corporation and a wholly-owned subsidiary of Pfizer Inc, having a place of business at 2800 Plymouth Road, Ann Arbor, MI 48105 ("Warner").
AMENDED AND RESTATED MARKETING COLLABORATION AGREEMENTMarketing Collaboration Agreement • May 15th, 2018 • Mogo Finance Technology Inc. • Finance services • Ontario
POSTMEDIA NETWORK INC. a corporation duly incorporated pursuant to the laws of Canada, having its principal office at 365 Bloor Street East, 12th Floor, Toronto, ON M4W 3L4 (“Postmedia”)
AMENDMENT #3 TO THE AMENDED AND RESTATED RESEARCH, DEVELOPMENT AND MARKETING COLLABORATION AGREEMENT BETWEEN ONYX PHARMACEUTICALS, INC. AND WARNER-LAMBERT COMPANYMarketing Collaboration Agreement • November 14th, 2001 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances)
THIS AMENDMENT #3 to the Amended and Restated Research, Development and Marketing Collaboration Agreement dated as of May 2, 1995 (“Third Amendment”) is made and entered into on August 6, 2001 (the “Amendment Date”), by and between Onyx Pharmaceuticals, Inc., a Delaware corporation having its principal place of business at 3031 Research Drive, Richmond, California 94806 (“Onyx”), and the Warner-Lambert Company, a Delaware corporation and a wholly-owned subsidiary of Pfizer Inc, having a place of business at 2800 Plymouth Road, Ann Arbor, MI 48105 ("Warner").
AMENDMENT #3 TO THE AMENDED AND RESTATED RESEARCH, DEVELOPMENT AND MARKETING COLLABORATION AGREEMENT between ONYX PHARMACEUTICALS, INC. and WARNER-LAMBERT COMPANYMarketing Collaboration Agreement • November 9th, 2006 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances)
This Amendment #3 to the Amended and Restated Research, Development and Marketing Collaboration Agreement dated as of May 2, 1995 (“Third Amendment”) is made and entered into on August 6, 2001 (the “Amendment Date”), by and between Onyx Pharmaceuticals, Inc., a Delaware corporation having its principal place of business at 3031 Research Drive, Richmond, California 94806 (“Onyx”), and the Warner-Lambert Company, a Delaware corporation and a wholly-owned subsidiary of Pfizer Inc, having a place of business at 2800 Plymouth Road, Ann Arbor, MI 48105 (“Warner”).
